Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Products under Development by Stage of Development | 8 | 1 |
| Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Products under Development by Therapy Area | 9 | 1 |
| Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Products under Development by Indication | 10 | 1 |
| Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Products under Development by Companies | 13 | 2 |
| Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Therapeutics Assessment | 15 | 6 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 1 |
| Assessment by Route of Administration | 17 | 2 |
| Assessment by Molecule Type | 19 | 2 |
| Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Companies Involved in Therapeutics Development | 21 | 5 |
| Alteogen Inc. | 21 | 1 |
| Chengdu Kanghong Pharmaceuticals Group Co., Ltd. | 22 | 1 |
| Clearside BioMedical, Inc. | 23 | 1 |
| Formycon AG | 24 | 1 |
| Regeneron Pharmaceuticals, Inc. | 25 | 1 |
| Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Drug Profiles | 26 | 31 |
| (aflibercept + nesvacumab) Drug Profile | 26 | 1 |
| (aflibercept + rinucumab) Drug Profile | 27 | 2 |
| (aflibercept + triamcinolone acetonide) Drug Profile | 29 | 3 |
| aflibercept Drug Profile | 32 | 11 |
| aflibercept biosimilar Drug Profile | 43 | 1 |
| aflibercept biosimilar Drug Profile | 44 | 1 |
| conbercept Drug Profile | 45 | 2 |
| SL-002 Drug Profile | 47 | 1 |
| SL-186 Drug Profile | 48 | 1 |
| SL-188 Drug Profile | 49 | 1 |
| THR-317 Drug Profile | 50 | 3 |
| ziv-aflibercept (recombinant) Drug Profile | 53 | 4 |
| Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Dormant Projects | 57 | 1 |
| Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Discontinued Products | 58 | 1 |
| Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Featured News &Press Releases | 59 | 12 |
| Jun 08, 2016: NICE draft recommendation on the use of aflibercept (EYLEA) for management of branch retinal vein occlusion goes against Royal College of Ophthalmologists guidance | 59 | 1 |
| May 02, 2016: Oncurious NV, BioInvent and NMTRC Initiating Phase I/IIa Study with TB-403 for the Treatment of Medulloblastoma | 60 | 1 |
| Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion | 61 | 1 |
| Mar 15, 2016: BioInvent and Oncurious Partner with US Research Consortium to Accelerate Phase I/IIa Trial of TB-403 | 61 | 1 |
| Mar 01, 2016: Aflibercept in myopic choroidal neovascularization: Added benefit not proven | 62 | 1 |
| Feb 29, 2016: Formycon discloses details on second pipeline product FYB203 is a biosimilar for Eylea (aflibercept) | 63 | 1 |
| Jan 07, 2016: BioInvent announces FDA acceptance of the Investigational New Drug application for the phase I/IIa study with TB-403 | 63 | 1 |
| Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration | 64 | 1 |
| Oct 30, 2015: Bayer Receives EU Approval for EYLEA for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization | 65 | 1 |
| Sep 25, 2015: Bayer s Eye Drug Recommended for EU Approval in Fifth Indication | 65 | 1 |
| Sep 18, 2015: Three-Year Results with EYLEA Show Sustained Improvement in Vision for People with Diabetic Macular Edema | 66 | 1 |
| Jul 21, 2015: NICE gives green light to aflibercept solution for treating serious eye condition | 67 | 1 |
| Jun 26, 2015: Bayer Receives Approval for EYLEA for the Treatment of Retinal Vein Occlusion in Japan | 67 | 1 |
| Jun 02, 2015: NICE Recommended Aflibercept Solution For Injection For Treating Serious Diabetic Eye Condition In Final Draft Guidance | 68 | 1 |
| May 06, 2015: Data presented at ARVO 2015 further showcase the real-world efficacy of EYLEA in UK clinical practice | 68 | 3 |
| Appendix | 71 | 2 |
| Methodology | 71 | 1 |
| Coverage | 71 | 1 |
| Secondary Research | 71 | 1 |
| Primary Research | 71 | 1 |
| Expert Panel Validation | 71 | 1 |
| Contact Us | 71 | 1 |
| Disclaimer | 72 | 1 |